Optimizing heart failure pathways to enhance patient care: the Program to Optimize Heart Failure Patient Pathways (PRO-HF)

Data de publicação: Data Ahead of Print:

Autores da FMUP

  • Ricardo Manuel Alves Monteiro Fontes De Carvalho

    Autor

Participantes de fora da FMUP

  • Patwala, Ashish
  • Barker, Diane
  • Da Costa, Antoine
  • Bayard, Geoffrey
  • Brunner-La Rocca, Hans-Peter
  • de la Fuente, Luis
  • Goralski, Marc
  • Mahon, Niall G.
  • Roque, David
  • Santos, Mario
  • Yousef, Zaheer
  • Ben Hamouda, Hela
  • Teal, Mark
  • Christory, Francois
  • Ahmed, Fozia Zahir
  • Mebazaa, Alexandre

Unidades de investigação

Abstract

AimsMany European healthcare providers struggle to adopt multidisciplinary, integrated care pathways for people with heart failure (HF) as recommended by the European Society of Cardiology. PRO-HF (Program to Optimize Heart Failure Patient Pathways) was developed to help clinicians identify strengths, gaps, and shortcomings in their HF pathways and support tailored interventions to optimize pathways and enhance patient care. We report initial findings from baseline assessments of HF pathway characteristics and challenges from 10 hospitals in six European countries (France, Ireland, Portugal, Spain, The Netherlands, and United Kingdom).Methods and resultsBaseline assessments were holistic appraisals of full HF services to calibrate current status and development needs and assist management teams in prioritizing improvement projects. Assessments were performed using a comprehensive checklist of measures covering the HF patient journey from diagnosis to ongoing follow-up. These included a digital survey sent to full HF care teams and one-to-one interviews. The digital survey focused on four key areas (HF outpatient clinic; remote patient management; efficient device implantation and inpatient pathways; and network maximization) and 16 dimensions of excellence. Priority areas and themes for action identified in baseline assessments were (i) provision of HF specialist care; (ii) data capture and analysis; (iii) institutional care protocols; (iv) hospital-wide strategies; and (v) multidisciplinary teams (MDTs). Suboptimal specialist care of emergency inpatients was an issue at all hospitals and prioritized at 8/10. Availability and accessibility of data on patients, activities, and outcomes was an issue at all hospitals and prioritized by 4/10. A lack of clear protocols, templates, and tools for some HF activities created variability in patient care (e.g., HF specialist consultations, diagnostic testing, follow-up appointments, medications, and device eligibility) and inefficient use of clinician time. This made it difficult to initiate new technologies (e.g., remote patient monitoring) due to the risk of overburdening staff. MDTs were frequently understaffed. Multiple interventions were identified to address gaps and shortcomings that could be tailored to specific needs of individual hospitals (e.g., inpatient pathway optimization, creation/optimization of HF outpatient clinics, development of an HF performance dashboard, enhancement of protocol adherence, streamlining cardiac resynchronisation therapy pathways, and MDT coordination).ConclusionsPRO-HF provides a valuable opportunity to identify gaps and significant shortcomings in HF pathways in European hospitals. Preliminary findings from hospitals that have initiated suggested changes to address these challenges are encouraging, though longer-term follow-up from more hospitals is needed to confirm the impact of PRO-HF on HF pathway optimization and patient care.

Dados da publicação

ISSN/ISSNe:
2055-5822, 2055-5822

ESC heart failure  The Heart Failure Association of the European Society of Cardiology

Tipo:
Article
Páginas:
2481-2481
Link para outro recurso:
www.scopus.com

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • Heart failure; HF pathway; HF protocol; HF specialist care; Multidisciplinary team; Pathway optimization; PRO-HF

Proyectos asociados

Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684

Investigador Principal: João Pedro Melo Marques Pinho Ferreira

Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022

Screening of Fabry Disease in Portuguese Patients With Idiopathic Cardiomyopathies (F-CHECK) - NCT05409846

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Observacional Académico (F-CHECK) . Sanofi . 2022

The Impact of Obesity on Cardiac Function and Morphology in Aortic Stenosis

Investigador Principal: Ricardo Manuel Alves Monteiro Fontes de Carvalho

Estudo Clínico Académico (Obesity) . 2020

Suboptimal control of cardiovascular risk factors in myocardial infarction survivors

Investigador Principal: Ricardo Manuel Alves Monteiro Fontes de Carvalho

Estudo Clínico Académico (myocard) . 2020

Modeling Aortic Stenosis progression: impact on follow-up, treatment, and survival

Investigador Principal: Ricardo Manuel Alves Monteiro Fontes de Carvalho

Estudo Clínico Académico . 2022

Epicardial adipose tissue volume is not an independent predictor of atrial fibrillation recurrence after ablation

Investigador Principal: Ricardo Manuel Alves Monteiro Fontes de Carvalho

Estudo Clínico Académico . 2022

Flow-status in severe aortic stenosis for percutaneous valve implantation: Should we follow the flow?

Investigador Principal: Ricardo Manuel Alves Monteiro Fontes de Carvalho

Estudo Clínico Académico . 2022

Cardiovascular Impact of Metabolic Syndrome: From Mechanisms to New Treatment Targets

Investigador Principal: Ricardo Manuel Alves Monteiro Fontes de Carvalho

Estudo Clínico Académico . 2021

Citar a publicação

Partilhar a publicação